Novel mutations target distinct subgroups of medulloblastomaGiles Robinson, Richard J. Gilbertson, Xiang Chen et al.|Nature|2012Cited by 853
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung CancerJoachim von Pawel, Markus F. Renschler, Robert M. Jotte et al.|Journal of Clinical Oncology|2014Cited by 344